Kristina Anna Ingrid Stefansson

Dr. Kristina Anna Ingrid Stefansson

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MBMaria Brattsand
Maria Brattsand
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
CLChristine Lundh
Christine Lundh
YHYlva Haasum
Ylva Haasum
TOTorbj
Torbj

1 January 2008 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
MBMaria Brattsand
Maria Brattsand
DRDirk Roosterman
Dirk Roosterman
CKCordula Kempkes
Cordula Kempkes
Georgeta BochevaGeorgeta Bocheva
Georgeta Bocheva
TETorbjörn Egelrud
Torbjörn Egelrud

27 September 2002 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
MHMaria L. Henriksson
Maria L. Henriksson
MFMatthew S. Francis
Matthew S. Francis
APAlex Peden
Alex Peden
MAMargareta Aili
Margareta Aili
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
BHBengt Hallberg
Bengt Hallberg
14‐3‐3 proteins play an important role in a multitude of signalling pathways. The interactions between 14‐3‐3 and other signalling proteins, such as Raf and KSR (kinase suppressor of Ras), occur in a phospho‐specific manner. Recently, a phosphorylation‐independent interaction has been reported to occur between 14‐3‐3 and several proteins, for example 5‐phosphatase, p75NTR‐associated cell death executor (NADE) and the bacterial toxin Exoenzyme S (ExoS), an ADP‐ribosyltransferase from Pseudomonas aeruginosa. In this study we have identified the amino acid residues on ExoS, which are responsible for its specific interaction with 14‐3‐3. Furthermore, we show that a peptide derived from ExoS, containing the 14‐3‐3 interaction site, effectively competes out the interaction between ExoS and 14‐3‐3. In addition, competition with this peptide blocks ExoS modification of Ras in our Ras modification assay. We show that the ExoS protein interacts with all isoforms of the 14‐3‐3 family tested. Moreover, in vivo an ExoS protein lacking the 14‐3‐3 binding site has a reduced capacity to ADP ribosylate cytoplasmic proteins, e.g. Ras, and shows a reduced capacity to change the morphology of infected cells.

1 July 2009 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
MBMaria Brattsand
Maria Brattsand
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
THThomas Hubiche
Thomas Hubiche
SNStefan K. Nilsson
Stefan K. Nilsson
TETorbjörn Egelrud
Torbjörn Egelrud

1 January 2006 in Biological Chemistry
Verified
Journal Article
Closed access
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
MBMaria Brattsand
Maria Brattsand
ANAnnelii Ny
Annelii Ny
BGBo Glas
Bo Glas
TETorbjörn Egelrud
Torbjörn Egelrud
We have previously presented evidence that two human kallikrein-related peptidases, KLK5 (hK5, stratum corneum tryptic enzyme, SCTE) and KLK7 (hK7, stratum corneum chymotryptic enzyme, SCCE), which are abundant in the stratum corneum, may be involved in desquamation. Since we had noted that not all trypsin-like activity in the plantar stratum corneum could be ascribed to KLK5, we set out to identify other skin proteases with similar primary substrate specificity. Here we describe purification of a protease identified as KLK14 from plantar stratum corneum, and show that this enzyme may be responsible for as much as 50% of the total trypsin-like activity in this tissue, measured as activity towards a chromogenic substrate cleaved by a wide variety of enzymes with trypsin-like specificity. This was in spite of very low levels of KLK14 protein compared to KLK5 and KLK7. KLK14 could be detected by immunoblotting in normal superficial stratum corneum of all individuals examined. The majority of KLK14 in the plantar stratum corneum is present in its catalytically active form. KLK14 could be immunohistochemically detected in sweat ducts, preferentially in the intraepidermal parts (the acrosyringium), and in sweat glands. The role played by this very efficient protease under normal and disease conditions in the skin remains to be elucidated.

20 October 2021 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Open access
MMMalin Mickelsson
Malin Mickelsson
ESElisabet Söderström
Elisabet Söderström
KSKristina Anna Ingrid Stefansson
Kristina Anna Ingrid Stefansson
JAJonas Andersson
Jonas Andersson
SSStefan Söderberg
Stefan Söderberg
JHJohan Hultdin
Johan Hultdin
Tobacco consumption is a renal risk factor, but the effects on the estimated glomerular filtration rate (eGFR) remain unclear. We aimed to evaluate the possible impact of using tobacco products (smoking and snus) on eGFR based on creatinine or cystatin C. We used a first cohort with 949 participants and a second cohort with 995 participants; none had pre-existing renal disease. All subjects donated a blood sample and completed a questionnaire, including questions about tobacco use. To assess the effect on eGFR, hierarchical multiple linear regression models were used. Active smoking associated independently with a higher eGFRcreatinine in all subjects (p < 0.001; β = 0.11). Further analyses stratified for sex, showed similar findings for men (p < 0.001; β = 0.14) and for women (p = 0.026; β = 0.10). eGFRcystatin C was significantly associated with active smoking in all subjects (p = 0.040; β = −0.05), but no association was seen after stratification for sex. Snus did not associate with eGFR. In conclusion, smoking associated significantly with a higher eGFRcreatinine. The mechanism may be renal hyperfiltration of smaller molecules such as creatinine. This is probably caused by substances from smoked tobacco other than nicotine, as no effect was seen for snus.